350 reports of this reaction
1.6% of all CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES reports
#18 most reported adverse reaction
HOSPITALISATION is the #18 most commonly reported adverse reaction for CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, manufactured by Jazz Pharmaceuticals, Inc.. There are 350 FDA adverse event reports linking CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES to HOSPITALISATION. This represents approximately 1.6% of all 22,248 adverse event reports for this drug.
Patients taking CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES who experience hospitalisation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HOSPITALISATION is a less commonly reported adverse event for CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, but still significant enough to appear in the safety profile.
In addition to hospitalisation, the following adverse reactions have been reported for CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES:
The following drugs have also been linked to hospitalisation in FDA adverse event reports:
HOSPITALISATION has been reported as an adverse event in 350 FDA reports for CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES. This does not prove causation, but indicates an association observed in post-market surveillance data.
HOSPITALISATION accounts for approximately 1.6% of all adverse event reports for CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, making it a notable side effect.
If you experience hospitalisation while taking CALCIUM, MAGNESIUM, POTASSIUM, AND SODIUM OXYBATES, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.